# Axovant Gene Therapies Ltd. (AXGT)

Source: https://www.quantisnow.com/company/AXGT
Generated: 2026-11-20T18:07:22.129Z

- Ticker: AXGT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Major Pharmaceuticals
- IPO year: n/a

## Latest AXGT news and filings

- 2020-11-10 12:00 UTC [Axovant Gene Therapies Announces Name Change to Sio Gene Therapies](https://www.quantisnow.com/insight/axovant-gene-therapies-announces-name-change-to-sio-gene-therapies-147768)
- 2020-11-09 12:00 UTC [Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases](https://www.quantisnow.com/insight/axovant-gene-therapies-announces-fda-clearance-of-ind-for-axo-aav-gm2-144561)
- 2020-10-29 20:01 UTC [Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020](https://www.quantisnow.com/insight/axovant-gene-therapies-to-present-axo-lenti-pd-program-update-during-virtual-128495)
- 2020-10-27 12:45 UTC [Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years](https://www.quantisnow.com/insight/why-gastrointestinal-gi-cancer-drugs-are-expected-to-see-significant-120839)
- 2020-10-22 11:00 UTC [Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020](https://www.quantisnow.com/insight/axovant-gene-therapies-to-host-virtual-parkinsons-disease-rd-day-113449)
- 2020-10-09 11:00 UTC [Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis](https://www.quantisnow.com/insight/axovant-gene-therapies-receives-rare-pediatric-disease-designation-for-axo-aav-gm1-91472)
- 2020-10-08 11:00 UTC [Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer](https://www.quantisnow.com/insight/axovant-gene-therapies-strengthens-board-of-directors-and-announces-new-88935)
- 2020-10-06 11:00 UTC [Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy](https://www.quantisnow.com/insight/axovant-announces-positive-six-month-follow-up-data-from-second-cohort-of-83854)
- 2020-10-05 11:00 UTC [Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th](https://www.quantisnow.com/insight/axovant-to-participate-in-upcoming-october-conferences-and-provide-axo-lenti-pd-81462)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AXGT
- Earnings history: https://www.quantisnow.com/earnings/AXGT
- Dividend history: https://www.quantisnow.com/dividends/AXGT
- Insider transactions: https://www.quantisnow.com/insiders/AXGT
- Options chain: https://www.quantisnow.com/options/AXGT
- SEC 8-K filings only: https://www.quantisnow.com/company/AXGT/8-k
- RSS and alerts for AXGT: https://www.quantisnow.com/docs/rss-feeds.md
